LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 16

Search options

  1. Article ; Online: Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.

    Fakhri, Bita / Emechebe, Nnadozie / Manzoor, Beenish S / Jawaid, Dureshahwar / Alhasani, Hasan / Edwards, Melanie / Tuncer, Hande H

    JCO oncology practice

    2024  , Page(s) OP2300630

    Abstract: Purpose: Real-world evidence comparing health care resource use (HRU) and costs between novel targeted therapies among patients with chronic lymphocytic leukemia (CLL) is lacking. We compared all-cause and CLL-specific HRU and costs between patients ... ...

    Abstract Purpose: Real-world evidence comparing health care resource use (HRU) and costs between novel targeted therapies among patients with chronic lymphocytic leukemia (CLL) is lacking. We compared all-cause and CLL-specific HRU and costs between patients initiated on B-cell lymphoma 2 inhibitor (venetoclax)- or Bruton tyrosine kinase inhibitor (BTKi)-based regimens in the second-line (2L) setting.
    Methods: This is a retrospective observational study using Optum Clinformatics Data Mart of adult patients with CLL/small lymphocytic lymphoma who received 2L venetoclax- or BTKi-based regimens (January 2018-December 2021) for the first time and had ≥one CLL diagnostic claim after 2L initiation and ≥two claims for venetoclax or BTKi. Baseline characteristics were balanced using stabilized inverse probability of treatment weights. Mean monthly cost difference (MMCD) between cohorts for all-cause and CLL-specific per patient per month (PPPM) costs was estimated. Rates of PPPM-HRU were compared between cohorts using rate ratios (RRs).
    Results: Of 280 patients, median age 75.5 years, 64.6% and 35.4% received BTKi- versus venetoclax-based regimens, respectively. Most BTKi-treated patients received monotherapy (88.4%), whereas 62.3% of venetoclax-treated patients received combination therapy with anti-CD20 agents. The median duration of 2L therapy was 11.6 and 11.0 months for BTKi versus venetoclax cohorts, respectively. All-cause total costs were lower for venetoclax versus BTKi (MMCD [SE], $-2,497.64 [$1,006.77] in US dollars (USD);
    Conclusion: Venetoclax was associated with total monthly cost savings versus BTKis, illustrating the economic value of time-limited venetoclax-based regimens in the 2L setting.
    Language English
    Publishing date 2024-04-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3028198-2
    ISSN 2688-1535 ; 2688-1527
    ISSN (online) 2688-1535
    ISSN 2688-1527
    DOI 10.1200/OP.23.00630
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7198: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies.

    Wang, Hanyin / Tuncer, Hande

    Case reports in hematology

    2018  Volume 2018, Page(s) 8207017

    Abstract: The value of combination therapy for refractory ITP is not well defined. We present the case of a 29-year-old male with severe ITP refractory to initial standard therapy including steroids, IVIG, and subsequent splenectomy, who was treated with the ... ...

    Abstract The value of combination therapy for refractory ITP is not well defined. We present the case of a 29-year-old male with severe ITP refractory to initial standard therapy including steroids, IVIG, and subsequent splenectomy, who was treated with the combination therapy of rituximab, romiplostim, and mycophenolate and eventually developed thrombocytosis requiring plateletpheresis. Our case highlights the importance of the need to understand predictors of response to standard upfront treatment of acute ITP.
    Language English
    Publishing date 2018-07-03
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2627639-2
    ISSN 2090-6579 ; 2090-6560
    ISSN (online) 2090-6579
    ISSN 2090-6560
    DOI 10.1155/2018/8207017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Photopheresis in solid organ transplant rejection.

    Marques, Marisa B / Tuncer, Hande H

    Journal of clinical apheresis

    2006  Volume 21, Issue 1, Page(s) 72–77

    Abstract: Photopheresis has become a key component in the therapeutic armamentarium of cutaneous T-cell lymphoma, graft-versus-host disease following stem cell transplant, and allograft rejection of solid organs such as heart. Although it is considered a new ... ...

    Abstract Photopheresis has become a key component in the therapeutic armamentarium of cutaneous T-cell lymphoma, graft-versus-host disease following stem cell transplant, and allograft rejection of solid organs such as heart. Although it is considered a new treatment modality in its present form, the field of phototherapy dates back thousands of years. In this review, the reader will learn more about the history of photopheresis and how it became a therapeutic alternative for patients with solid organ transplants. An extensive literature search will highlight the evidence-based benefits of photopheresis (or lack thereof). A discussion of the mechanism of action of photopheresis and the technical aspects of the procedure will also be covered. Since photopheresis may be the best tolerated form of immunomodulation, current promising, albeit preliminary data on its efficacy warrant further investigation and understanding.
    MeSH term(s) Graft Rejection/therapy ; History, 20th Century ; History, 21st Century ; Humans ; Immune System/drug effects ; Immune System/radiation effects ; Organ Transplantation/methods ; Photopheresis/history ; Photopheresis/methods ; T-Lymphocytes/immunology
    Language English
    Publishing date 2006-04
    Publishing country United States
    Document type Historical Article ; Journal Article ; Review
    ZDB-ID 604912-6
    ISSN 1098-1101 ; 0733-2459
    ISSN (online) 1098-1101
    ISSN 0733-2459
    DOI 10.1002/jca.20089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1831: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

    Shadman, Mazyar / Manzoor, Beenish S / Sail, Kavita / Tuncer, Hande H / Allan, John N / Ujjani, Chaitra / Emechebe, Nnadozie / Kamalakar, Rajesh / Coombs, Catherine C / Leslie, Lori / Barr, Paul M / Brown, Jennifer R / Eyre, Toby A / Rampotas, Alexandros / Schuh, Anna / Lamanna, Nicole / Skarbnik, Alan / Roeker, Lindsey E / Bannerji, Rajat /
    Eichhorst, Barbara / Fleury, Isabelle / Davids, Matthew S / Alhasani, Hasan / Jiang, Dingfeng / Hill, Brian T / Schuster, Stephen J / Brander, Danielle M / Pivneva, Irina / Burne, Rebecca / Guerin, Annie / Mato, Anthony R

    Clinical lymphoma, myeloma & leukemia

    2023  Volume 23, Issue 7, Page(s) 515–526

    Abstract: Introduction: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings.: Materials and methods: Using ... ...

    Abstract Introduction: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings.
    Materials and methods: Using deidentified electronic medical records from the CLL Collaborative Study of Real-World Evidence, premature treatment discontinuation was assessed among FCR, BR, BTKi-based, and BCL-2-based regimen cohorts.
    Results: Of 1364 1L patients (initiated in 1997-2021), 190/13.9% received FCR (23.7% discontinued prematurely); 255/18.7% received BR (34.5% discontinued prematurely); 473/34.7% received BTKi-based regimens, of whom 28.1% discontinued prematurely; and 43/3.2% received venetoclax-based regimens, of whom 16.3% discontinued prematurely (venetoclax monotherapy: 7/0.5%, of whom 42.9% discontinued; VG/VR: 36/2.6%, of whom 11.1% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 25/13.2%; BR: 36/14.1%; BTKi-based regimens: 75/15.9%) and disease progression (venetoclax-based: 3/7.0%). Of 626 2L patients, 20/3.2% received FCR (50.0% discontinued); 62/9.9% received BR (35.5% discontinued); 303/48.4% received BTKi-based regimens, of whom 38.0% discontinued; and 73/11.7% received venetoclax-based regimens, of whom 30.1% discontinued (venetoclax monotherapy: 27/4.3%, of whom 29.6% discontinued; VG/VR: 43/6.9%, of whom 27.9% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 6/30.0%; BR: 11/17.7%; BTKi-based regimens: 60/19.8%; venetoclax-based: 6/8.2%).
    Conclusion: The findings of this study highlight the continued need for tolerable therapies in CLL, with finite therapy offering a better tolerated option for patients who are newly diagnosed or relapsed/refractory to prior treatments.
    MeSH term(s) Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Sulfonamides/adverse effects ; Disease Progression ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Agents/therapeutic use
    Chemical Substances venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides ; Antineoplastic Agents
    Language English
    Publishing date 2023-03-24
    Publishing country United States
    Document type Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2023.03.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation.

    Tuncer, Hande H / Rana, Naveed / Milani, Cannon / Darko, Angela / Al-Homsi, Samer A

    World journal of gastroenterology

    2011  Volume 18, Issue 16, Page(s) 1851–1860

    Abstract: Recognition and management of gastrointestinal and hepatic complications of hematopoietic stem cell transplantation has gained increasing importance as indications and techniques of transplantation have expanded in the last few years. The transplant ... ...

    Abstract Recognition and management of gastrointestinal and hepatic complications of hematopoietic stem cell transplantation has gained increasing importance as indications and techniques of transplantation have expanded in the last few years. The transplant recipient is at risk for several complications including conditioning chemotherapy related toxicities, infections, bleeding, sinusoidal obstruction syndrome, acute and chronic graft-versus-host disease (GVHD) as well as other long-term problems. The severity and the incidence of many complications have improved in the past several years as the intensity of conditioning regimens has diminished and better supportive care and GVHD prevention strategies have been implemented. Transplant clinicians, however, continue to be challenged with problems arising from human leukocyte antigen-mismatched and unrelated donor transplants, expanding transplant indications and age-limit. This review describes the most commonly seen transplant related complications, focusing on their pathogenesis, differential diagnosis and management.
    MeSH term(s) Diarrhea/etiology ; Gastrointestinal Diseases/etiology ; Gastrointestinal Hemorrhage/etiology ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hepatic Veno-Occlusive Disease/etiology ; Hepatitis B, Chronic/etiology ; Hepatitis C, Chronic/etiology ; Humans ; Iron Overload/etiology ; Liver Diseases/etiology ; Stomatitis/etiology
    Language English
    Publishing date 2011-12-19
    Publishing country United States
    Document type Editorial ; Review
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v18.i16.1851
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6039: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.

    Ujjani, Chaitra / Mato, Anthony / Hill, Brian T / Allan, John N / Lansigan, Frederick / Jacobs, Ryan / Skarbnik, Alan / Tuncer, Hande / Pagel, John / Brander, Danielle / Cheson, Bruce / Barr, Paul / Roeker, Lindsey E / Pu, Jeffrey / Shah, Nirav N / Goy, Andre / Schuster, Stephen J / Lamanna, Nicole / Sehgal, Alison /
    Tam, Constantine S / Shadman, Mazyar

    Blood and lymphatic cancer : targets and therapy

    2020  Volume 10, Page(s) 1–5

    Abstract: Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a ...

    Abstract Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.
    Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.
    Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).
    Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.
    Language English
    Publishing date 2020-08-24
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2673412-6
    ISSN 1179-9889 ; 1179-9889
    ISSN (online) 1179-9889
    ISSN 1179-9889
    DOI 10.2147/BLCTT.S262592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience.

    Tuncer, Hande H / Oster, Robert A / Huang, Shu T / Marques, Marisa B

    Transfusion

    2007  Volume 47, Issue 1, Page(s) 107–114

    Abstract: Background: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a diagnosis of exclusion when a patient presents with the sine qua non findings of thrombocytopenia and microangiopathic hemolytic anemia without an identifiable ... ...

    Abstract Background: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a diagnosis of exclusion when a patient presents with the sine qua non findings of thrombocytopenia and microangiopathic hemolytic anemia without an identifiable cause. Although most patients respond to therapeutic plasma exchange (TPE), a significant number of patients relapse. The aim was to determine if clinical, laboratory, and/or treatment features could predict response and/or relapse.
    Study design and methods: This study was a retrospective review of adults with TTP-HUS treated with TPE at our institution from January 1996 to February 2004.
    Results: The study population consisted of 90 patients (69% female) with mean age of 45 years and mostly obese (65%). The majority of cases were considered idiopathic. Ten patients died (11%) from the disease before achieving a response, whereas 79 percent were considered responders. Obesity and severe anemia at presentation were predictors of response to TPE (p = 0.0126 and p = 0.0071, respectively). Among the responders, 28 percent relapsed in a median of 14 months. Male sex, severe thrombocytopenia (mean +/- SD, 13 x 10(9) +/- 8 x 10(9)/L), and higher lactate dehydrogenase pre-/posttreatment ratio were associated with relapse (p values of 0.0141, 0.0199, and 0.0407, respectively). ADAMTS-13 values were not obtained on enough number of patients to provide important data.
    Conclusion: Although patient and laboratory characteristics associated with response and relapse were identified, there was significant overlap between patient groups. Thus, our findings offer preliminary evidence and do not yet justify short- or long-term changes in the management of patients with TTP-HUS.
    MeSH term(s) Adult ; Anemia/complications ; Anemia/physiopathology ; Cohort Studies ; Female ; Hemolytic-Uremic Syndrome/blood ; Hemolytic-Uremic Syndrome/complications ; Hemolytic-Uremic Syndrome/therapy ; Humans ; L-Lactate Dehydrogenase/blood ; Male ; Middle Aged ; Obesity/complications ; Plasma Exchange ; Predictive Value of Tests ; Prognosis ; Purpura, Thrombotic Thrombocytopenic/blood ; Purpura, Thrombotic Thrombocytopenic/complications ; Purpura, Thrombotic Thrombocytopenic/therapy ; Recurrence ; Retrospective Studies ; Severity of Illness Index ; Sex Factors ; Treatment Outcome
    Chemical Substances L-Lactate Dehydrogenase (EC 1.1.1.27)
    Language English
    Publishing date 2007-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/j.1537-2995.2007.01071.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 284: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.

    Eyre, Toby A / Lamanna, Nicole / Roeker, Lindsey E / Ujjani, Chaitra S / Hill, Brian T / Barr, Paul M / Lansigan, Erick / Cheson, Bruce D / Yazdy, Maryam / Allan, John N / Rhodes, Joanna / Schuster, Stephen J / Nabhan, Chadi / Skarbnik, Alan / Leslie, Lori / Islam, Prioty / Whitaker, Katherine / Coombs, Catherine C / Tuncer, Hande H /
    Pagel, John M / Jacobs, Ryan / Winter, Allison M / Bailey, Neil / Sitlinger, Andrea / Schuh, Anna H / Follows, George / Fox, Christopher P / Brander, Danielle M / Shadman, Mazyar / Mato, Anthony R

    Haematologica

    2021  Volume 106, Issue 1, Page(s) 284–287

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Pyrazoles/therapeutic use ; Pyrimidines/therapeutic use
    Chemical Substances Pyrazoles ; Pyrimidines
    Language English
    Publishing date 2021-01-01
    Publishing country Italy
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2019.241539
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

    Boissel, Laurent / Betancur, Monica / Wels, Winfried S / Tuncer, Hande / Klingemann, Hans

    Leukemia research

    2009  Volume 33, Issue 9, Page(s) 1255–1259

    Abstract: An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was ... ...

    Abstract An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was transfected into the NK-92 cell line by electroporation. In contrast to cDNA, mRNA resulted in high transfection efficiency (47.2 +/- 8% versus <5% for cDNA) with minimal effect on cell viability. NK-92 cells expressing anti-CD19 CAR killed previously resistant CD19+ B-ALL cell lines, as well as primary CLL cells and therefore may present a safe, cell-based, targeted treatment for patients with CLL.
    MeSH term(s) Antigens, CD19/genetics ; Base Sequence ; Cell Line, Tumor ; DNA Primers ; Electroporation ; Humans ; Killer Cells, Natural/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; RNA, Messenger/genetics ; Recombinant Fusion Proteins/genetics ; Transfection
    Chemical Substances Antigens, CD19 ; DNA Primers ; RNA, Messenger ; Recombinant Fusion Proteins
    Language English
    Publishing date 2009-01-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2008.11.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.

    Boissel, Laurent / Tuncer, Hande H / Betancur, Monica / Wolfberg, Adam / Klingemann, Hans

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

    2008  Volume 14, Issue 9, Page(s) 1031–1038

    Abstract: Natural killer (NK) cell-mediated cytotoxicity can control leukemia relapse while protecting patients from graft-versus-host disease (GVHD) after allogeneic stem cell transplant. Cord blood (CB) is rich in NK cell progenitors with similar properties of ... ...

    Abstract Natural killer (NK) cell-mediated cytotoxicity can control leukemia relapse while protecting patients from graft-versus-host disease (GVHD) after allogeneic stem cell transplant. Cord blood (CB) is rich in NK cell progenitors with similar properties of proliferation and cytotoxicity as adult blood NK cells. Hence, it is attractive to expand and potentially utilize these cells for adoptive immunotherapy. In this study, CB mononuclear cells were CD3-depleted by immunomagnetic microbead selection to remove T cells. This CD3(dep) CB-MNC fraction was then plated for ex vivo expansion, with or without a feeder layer of irradiated umbilical cord mesenchymal stem cells (UC-MSC), with or without cytokines that have been shown to be critical for NK expansion: IL-2, IL-15, IL-3, and FLT-3L. At an average of 2 weeks of culture, there was significantly higher expansion (64.7 +/- 8.4-fold) of CD56(+)/CD3(-) NK cells in the presence of the UC-MSC feeder layer and cytokines compared to controls (no increase with feeder layer only and 6.4 +/- 1.5-fold increase with cytokines only, P < .05). Contact between CD3(dep) CB-MNC cells and UC-MSC augmented NK expansion. The combination of all 4 cytokines was superior to IL-2 alone or 2 cytokines combinations: mean 64.7 +/- 8.4-fold expansion with 4 cytokines combination versus IL-2 alone, IL-2 + FLT-3L, IL-2 + IL-15 or IL-2 + IL-3 (12.2 +/- 2.0, 14.4 +/- 2.4, 10.4 +/- 4.1, 25.2 +/- 8.1 respectively). We also observed that only fresh CD3(dep) CB-MNC preparations could be expanded reliably, whereas frozen and thawed CD3(dep) CB-MNC cells did not expand consistently (mean fold increase 6.5 +/- 3.2). Cytotoxicity of expanded NK cells was compared with NK cells from fresh and overnight IL-2 activated CD3(dep) CB-MNC. Whereas fresh cells displayed no discernible killing, strong cytotoxicity against K562, Raji, REH, and SUP-B15 cells lines was noted after overnight activation in IL-2. Cytotoxicity of expanded NK cells against Raji, REH, and SUP-B15 was lower, which, however, correlated with a predominant expansion of CD56(+)/CD16(-) cells known to have less cytolytic activity than CD56(+)/CD16(+). To test the transfection efficiency in NK cells, fresh or expanded CD3(dep) CB-MNC cells were electroporated with either DNA or mRNA constructs for GFP. DNA had a low transfection efficiency (<10%), whereas the one for mRNA reached 52%, but at the cost of significant cell death. Our results suggest that CB NK cell progenitors can be expanded to obtain large numbers by using an irradiated feeder of UC-MSC. They maintain an elevated cytotoxic profile, and may be genetically manipulated-all characteristics that make them suitable for cellular therapies.
    MeSH term(s) Antigens, CD/immunology ; Cell Communication/immunology ; Cell Proliferation ; Coculture Techniques ; Cytokines/immunology ; Fetal Blood/cytology ; Fetal Blood/immunology ; Graft vs Host Disease/immunology ; Graft vs Host Disease/prevention & control ; Humans ; Immunity, Cellular ; Immunomagnetic Separation/methods ; Immunotherapy, Adoptive/methods ; K562 Cells ; Killer Cells, Natural/cytology ; Killer Cells, Natural/immunology ; Leukemia/immunology ; Leukemia/therapy ; Membrane Proteins/immunology ; Mesenchymal Stromal Cells/cytology ; Mesenchymal Stromal Cells/immunology ; Recurrence ; Umbilical Cord/cytology ; Umbilical Cord/immunology
    Chemical Substances Antigens, CD ; Cytokines ; Membrane Proteins ; flt3 ligand protein
    Language English
    Publishing date 2008-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1474865-4
    ISSN 1523-6536 ; 1083-8791
    ISSN (online) 1523-6536
    ISSN 1083-8791
    DOI 10.1016/j.bbmt.2008.06.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5082: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 462: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top